Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + Bendamustine in Relapsed/Refractory Hematological Malignancies
NCT02240719Phase 1Completed
- Sponsor
- University of California, Davis
- Start
- Oct 2014
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of everolimus in diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), follicular lymphoma (FL) and 3 more, sponsored by University of California, Davis. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Oct 2014; status: completed.
02
Drugs
everolimus
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Hodgkin lymphoma (HL)follicular lymphoma (FL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02240719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240719.